向烯氧化酶赋予了代谢脆弱性,并克服了HNSCC中的化学抵抗
Xinyuan Zhao1, Bing Guo2, Wenjuan Sun3
1Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|July 25, 2023
概括
烯环氧化酶 (SQLE) 通过稳定c-Myc.驱动头角状细胞癌 (HNSCC) 中的西斯普拉丁耐药性. 用terbinafine抑制SQLE为HNSCC提供了一个有前途的协同疗法.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 在治疗头角状细胞癌 (HNSCC) 方面,西斯普拉丁耐药性是一个重大挑战.
- 确定新的治疗点对于克服化疗抵抗至关重要.
研究的目的:
- 调查烯环氧化酶 (SQLE) 在HNSCC中对西斯普拉丁耐药性和瘤发生的作用.
- 阐明SQLE介导化学抵抗背后的分子机制.
- 评估针对HNSCC中SQLE的治疗潜力.
主要方法:
- 利用多个HNSCC瘤模型和内部患者队列.
- 进行了全面的转录基因分析.
- 进行了涉及蛋白质稳定,降解途径和脂质信号的机制研究.
- 采用了一个Sqle条件淘汰赛小鼠模型.
- 评估了terbinafine和cisplatin在临床前环境中的协同效应.
主要成果:
- 通过胆固醇依赖的途径,SQLE被确定为HNSCC中化学抵抗和瘤发生的关键驱动因素.
- SQLE通过防止其在基因中介的降解来稳定c-Myc,这对于c-Myc转录活性至关重要.
- 抑制SQLE会破坏脂质内的Akt信号,导致c-Myc的不稳定.
- 正如淘汰赛模型所示,SQLE在HNSCC的启动和进展中发挥着关键作用.
- 与特比纳和西斯普拉丁的联合治疗表明,在抑制瘤生长方面具有强大的协同效应.
结论:
- 通过c-Myc调节,SQLE是HNSCC中西斯普拉丁耐药性和瘤发生的关键调解者.
- 准SQLE为HNSCC提供了一个有前途的治疗策略.
- 将特比纳芬等SQLE抑制剂与西斯普拉丁结合起来,为对西斯普拉丁无反应的HNSCC患者提供了潜在的治疗方法.
更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.4K
11:28Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
8.6K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
